| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]．CA Cancer J Clin，2020，70(1)：7-30.
|
| [2] |
Wei W, Zeng H, Zheng R, et al.Cancer registration in China and its role in cancer prevention and control[J]．Lancet Oncol, 2020，21(7)：e342-e349.
|
| [3] |
Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negativebreast cancers: subtypes and treatment strategies[J]. Cancer Cell, 2019, 35(3)：428-440.
|
| [4] |
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer [J]. N Engl J Med, 2010, 363(20): 1938-1948.
|
| [5] |
刘飞，耿翠芝，吴云艳，等．组蛋白甲基转移酶EZH2基因在三阴性乳腺癌中的研究进展[J/CD]．中华乳腺病杂志(电子版), 2019，13(1)：50-53.
|
| [6] |
Zhang K, Liu P, Tang H, et al.AFAP1-AS1 promotes epithelial-mesenchymal transition and tumorigenesis hrough Wnt/β-catenin signaling pathway in triple-negative breast cancer[J]．Front Pharmacol, 2018, 9：1248.
|
| [7] |
International Human Genome Sequencing C. Finishing the euchromatic sequence of the human genome [J]. Nature, 2004, 431(7011): 931-945.
|
| [8] |
Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs [J]. Cell, 2009, 136(4): 629-641.
|
| [9] |
Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology [J]. Cancer Discov, 2011, 1(5): 391-407.
|
| [10] |
Wang X, Chen T, Zhang Y, et al.Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p/HOXC6 signaling pathway[J]. J Cell Physiol, 2019，234(8)：13 303-13 317.
|
| [11] |
Hu WL, Jin L, Xu A, et al. GUARDIN is a p53-responsive long non-coding RNA that is essential for genomic stability [J]. Nat Cell Biol, 2018, 20(4): 492-502.
|
| [12] |
Sas-Chen A, Aure MR, Leibocich L, et al. LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer [J]. EMBO Mol Med, 2016, 8(9): 1052-1064.
|
| [13] |
Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer[J]．Ann Oncol, 2009, 20(5)：862-867.
|
| [14] |
Lo YH, Ho PC, Zhao H, et al. Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016)[J]. Anticancer Res, 2011，31(3)：789-795.
|
| [15] |
Wang YL, Overstreet AM, Chen MS, et al. Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR[J]．Oncotarget，2015，6(13)：11 150-11 161.
|
| [16] |
Kim SB, Dent R, Im SA, et al.Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]．Lancet Oncol, 2017，18(10)：1360-1372.
|
| [17] |
Lin A, Hu Q, Li C, et al.The LINK-A lncRNA interacts with PtdIns(3，4，5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors[J]．Nat Cell Biol, 2017，19(3)：238-251.
|
| [18] |
Sonnenblick A，de Azambuja E，Azim HA，et al.An update on PARP inhibitors -moving to the adjuvant setting[J]．Nat Rev Clin Oncol, 2015，12(1)：27-41.
|
| [19] |
Loibl S, O’Shaughnessy J, Untch M, et al.Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomized, phase 3 trial[J]．Lancet Oncol, 2018，19(4)：497-509.
|
| [20] |
Zhang Y, He Q, Hu Z, et al.Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer[J]．Nat Struct Mol Biol, 2016，23(6)：522-530.
|
| [21] |
de Silva HC，Lin MZ，Phillips L, et al.IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer[J]．Cell Mol Life Sci, 2019，76(10)：2015-2030.
|
| [22] |
Guo B, Wu S, Zhu X, et al. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression [J]．EMBO J, 2020，39(1)．
|
| [23] |
Jiang D, Wang C, He J. Long non-coding RNA DGCR5 incudes tumorigenesis of triple-negative breast cancer by affecting Wnt/β-catenin signaling pathway[J]. J BUON, 2020，25(2)：702-708.
|
| [24] |
Hua K, Deng X, Hu J, et al.Long noncoding RNA HOST2, working as a competitive endogenous RNA, promotes STAT3-mediated cell proliferation and migration via decoying of let-7b in triple-negative breast cancer[J]．J Exp Clin Cancer Res, 2020，39(1)：58.
|
| [25] |
Wang Y, Wu S, Zhu X, et al.LncRNA-encoded polypeptide ASRPS inhibits triple-negative breast cancer angiogenesis[J]. J Exp Med, 2020，217(3): jem.20190950.
|
| [26] |
Xu Z, Liu C, Zhao Q, et al.Long non-coding RNA CCAT2 promotes oncogenesis in triple-negative breast cancer by regulating stemness of cancer cells[J]. Pharmacol Res, 2020，152：104628.
|
| [27] |
Adriaens C, Standaert L, Barra J, et al.p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity[J]．Nat Med, 2016，22(8)：861-868.
|
| [28] |
Yang C, Li Z, Li Y, et al.Long non-coding RNA NEAT1 overexpression is associated with poor prognosis in cancer patients: a systematic review and meta-analysis.[J]．Oncotarget, 2017, 8(2)：2672-2680.
|
| [29] |
Pickard MR, Williams GT. Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy[J]．Breast Cancer Res Treat, 2014，145(2)：359-370.
|
| [30] |
Chen J, Zhu M, Zou L, et al.Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO[J]．Acta Biochim Biophys Sin (Shanghai), 2020，52(8)：801-809.
|
| [31] |
Jiang YZ, Liu YR, Xu XE, et al. Transcriptome analysis of triple-negative breast cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value [J]. Cancer Res, 2016, 76(8): 2105-2114.
|
| [32] |
Liu YR, Jiang YZ, Xu XE, et al.Comprehensive transcriptome profiling reveals multigene signatures in triple-negative breast cancer[J]．Clin Cancer Res, 22(7)：1653-1662.
|
| [33] |
Jadaliha M, Zong X, Malakar P, et al.Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER-negative lymph node-negative breast cancer[J]．Oncotarget, 2016，7(26)：40 418-40 436.
|